Advisory Board and Editors Oncology
Altijana Hromić-Jahjefendić
Dr. Altijana Hromić-Jahjefendić is an associate professor at the Genetics and Bioengineering Department at International University of Sarajevo, Bosnia and Herzegovina. She obtained her bachelor's degree in chemistry and master's degree in Biochemistry and Molecular Biomedicine at Graz University of Technology, Austria. After that she worked for Austrian Center of Industrial Biotechnology and continued to pursue her PhD degree in Biochemistry and Molecular Biomedicine with the focus on Structural biology. Since 2018. she works as professor at International University of Sarajevo at the Genetics and Bioengineering Department. She authored many scientific publications with international colleagues in the field of COVID-19 and cancer research.
Lei Huang
Dr. Lei Huang is a cancer epidemiologist, translational oncologist, digestive surgeon, surgical oncologist, and gastroenterologist. He has published about 50 papers in SCI(E)-indexed journals including Gut, Annals of Surgery, BMC Medicine, JAMA Surgery, Clinical Cancer Research, Cancer Immunology Research, International Journal of Cancer, EBioMedicine, and Gastric Cancer. His works have been cited for about 1000 times.
Dr. Huang has served on the editorial board of Frontiers in Oncology, World Journal of Gastrointestinal Oncology, PeerJ, Medicine, and Translational Cancer Research, and Frontiers in Surgery. He has been peer reviewer for about 50 SCI(E)-indexed journals including Annals of Internal Medicine, Annals of Surgery, Clinical Cancer Research, Journal of the National Comprehensive Cancer Network-JNCCN, Cancer Letters, Oncoimmunology, and Oncologist. He was selected as Best Reviewer for Annals of Internal Medicine twice in 2017 and 2019.
Dr. Huang has been invited to give oral presentations in the ASCO Annual Meeting and International Gastric Cancer Congress (IGCC), and has received Merit Awards in the ESMO Annual Meeting and Awards for Young Investigators in the IGCC.
His research interests majorly cover the epidemiological, clinical, and translational aspects of digestive cancers. He has successfully coordinated several large international investigations with participants from the US and about 20 European countries.
Jose MG Izarzugaza
Associate Professor at the Technical University of Denmark (DTU). As a senior scientist in Prof. Søren Brunak's group at the Center for Biological Sequence Analysis (CBS), I have a profound interest in different aspects of next generation sequencing (NGS) data analysis. This covers a broad spectrum of scenarios and applications. Actively involved in the Genome Denmark initiative, with two main goals: to assemble and annotate the first draft of the Danish reference genome and to identify viruses driving cancer. Other current projects include the prediction of the pathogenicity of mutations in the protein kinase superfamily for the TCGA/ICGC Pancancer initiative.
Jayashree Kalpathy-Cramer
Research interests include the use of image processing and machine learning techniques for medical image analysis and retrieval, imaging for radiation therapy, survival analysis for cancer, information retrieval, and statistical modeling.
Alex Kentsis
Assistant Professor of Pediatrics at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University.
He leads research in the functional proteomics and genomic plasticity of refractory childhood cancers.
Imran Khan
Dr. Imran Khan is a postdoctoral fellow at the Department of Radiation Oncology, Mayo Clinic.
His work focuses on translational research, particularly for human tumors (glioma, brain metastasis, colon cancer and PDAC) investigating the mechanisms of tumor aggressiveness, establishing new effective treatments, and finding new diagnostic and prognostic biomarkers in in-vitro, in-vivo, and ex-vivo model systems.
Takeshi Kurita
I am a Professor of Biology at the Institute of Science Tokyo. My research interest lies in the molecular and cellular basis of development and reproduction, two fundamental processes for all multicellular organisms. I am particularly interested in the cell and tissue communications that regulate these processes. In embryonic development, interactions between tissues of different cell lineages drive organ formation by activating genetic and epigenetic programs for tissue patterning and cellular differentiation. Tissue interaction also plays a fundamental role in mammalian reproduction as it mediates the actions of sex steroid hormones in reproductive organs. Deregulation of signaling pathways that control tissue communications could lead to conditions such as cancer. Thus, I also investigate the molecular pathogenesis of disorders in reproductive and hormone-target organs. Since mammalian development and reproductive functions are controlled by complex crosstalk among multiple tissues, organs, and systems, we primarily use in vivo mouse models for the investigation.
Understanding the molecular mechanisms underlying the fundamental process of life is a goal of our research. In addition, our research also aims to improve human health through translational research based on the knowledge obtained through basic research.
Hang Fai Kwok
Prof Kwok’s research interests mainly focus on the development of novel monoclonal antibodies and venom-based peptides as prototype drugs for anticancer and anti-inflammatory therapies. In addition, Prof. Kwok’s research group is also expanding scientific knowledge and research in the areas of existing and novel cancer biomarkers such as 1) matricellular protein — OPN, 2) metalloproteinase — ADAM17 & ADAMTS5, 3) DNA replication licensing factor — MCM proteins, 4) small GTP binding protein — RAN, as well as immunotherapy markers (e.g. PD-1/PD-L1) in order to identify and validate their prognostic and therapeutic values according to the roles in hallmarks of cancer.
Julia Kzhyshkowska
1997: PhD Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow.
1997-2001: Postdoc at the University of Regensburg
2001-2007: Junior group leader/PI and lecturer, University of Heidelberg.
2007- 2010:Senior group leader/PI and senior lecturer, University of Heidelberg
2010-2013: Professor, head of the Lab for Cellular and Molecular Biology of Innate Immunity;
2013-permanent: Professor, head of Department for Innate Immunity and Tolerance, University of Heidelberg.
Brittany N Lasseigne
Brittany N. Lasseigne, PhD is an Assistant Professor of Cell, Developmental and Integrative Biology at The University of Alabama at Birmingham School of Medicine. She trained in Biotechnology, Science, and Engineering at Mississippi State University (B.S.) and the University of Alabama in Huntsville (Ph.D.) and completed a postdoctoral fellowship in genetics and genomics at the HudsonAlpha Institute for Biotechnology.
Her lab develops and applies genomic- and data-driven strategies (including single-cell and long-read sequencing) to discover biological signatures that might be used to improve patient care and provide insight into the cellular and molecular processes contributing to disease, especially for diseases impacting the brain and/or kidney. Their recent work includes prioritizing drug repurposing candidates for cancers and polycystic kidney disease, evaluating preclinical models and cross-species transcriptomic signatures to improve disease modeling, and applying single-cell and long-read technologies to neurological disease tissues to understand the role that context plays in disease etiology, progression, and treatment.
The Lasseigne Lab is currently focused on integrating genomics data, functional annotations, and patient information with machine learning and regulatory network approaches across diseases that impact the brain or kidney to discover novel mechanisms in disease etiology and progression, identify genome-driven therapeutic targets and opportunities for drug repositioning and repurposing, determine clinically-relevant biomarkers, and understand how cellular context contributes to these diseases. Collectively, these distinct projects all apply genetics and genomics to human diseases and build tools to accelerate future research. Their lab also develops data science software and analytical pipelines that are open-source, well-documented, and hosted by third-party code distributors, critical for facilitating reproducibility and enabling the research community to use the methods they develop.
Zhiming Li
Dr. Zhiming Li is an early career researcher at Columbia University. His primary research focus is on epigenetic inheritance and cancer epigenetics, and his long-term goals are to understand the fundamental mechanisms of epigenetic inheritance and how such mechanisms and epigenetic alterations are involved in tumorigenesis, which eventually would allow him to identify druggable targets for cancer intervention.
Ning Li
Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.